Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | RNF216 |
| Gene Name: | RNF216 |
| Protein Full Name: | E3 ubiquitin-protein ligase RNF216 |
| Alias: | E3 ubiquitin ligase TRIAD3; EC 6.3.2.-; Ring finger protein 216; RN216; TRIAD3; U7I1; UB7I1; Ubiquitin conjugating enzyme 7-interacting protein 1; ZIN; Zinc finger protein inhibiting NF-kappa-B |
| Mass (Da): | 99406 |
| Number AA: | 866 |
| UniProt ID: | Q9NWF9 ; A8K8N1 |
| Locus ID: | 54476 |
| COSMIC ID: | RNF216 |
| Gene location on chromosome: | 7p22.1 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19762 |
| Percent of cancer specimens with mutations: | 0.68 |
| Normal role description: | RNF216 is a cytoplasm localized protein with E3 ubiquitin ligase activity. RNF216 was found to promote the degradation of TRAF3, TLR4 and TLR9 through ubiquitination. Furthermore RNF216 was found to physically interact with receptor-interacting protein (RIP), IKKB, TNF and IL1 to cause inhibition of NF-kB activation. RNF216 appears to negatively regulate cell proliferation and growth pathways through direct inhibition or ubiquitination of growth factor mediated pathways. Thus RNF216 may act as a tumour suppressor protein. Mis-sense mutations in ovary and breast tumours have been identified but are not well characterized. |
| Commentary on involvement of protein in cancer: | No entry in Atlasgeneticsoncology.org |